Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)

Hamad Medical Corporation2 sites in 1 country400 target enrollmentDecember 2012

ConditionsAsthma

InterventionsMagnesium Sulfate

DrugsMagnesium Sulfate

Overview

Phase: Not Applicable
Intervention: Magnesium Sulfate
Conditions: Asthma
Sponsor: Hamad Medical Corporation
Enrollment: 400
Locations: 2
Primary Endpoint: Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma significantly reduce the time to clinical readiness for discharge?
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to investigate the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency.

Detailed Description

the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency follow asthma severity score and length of stay

Registry

clinicaltrials.gov

Start Date

December 2012

End Date

December 2015

Last Updated

12 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Hamad Medical Corporation

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Pediatric asthma patients with moderate to severe exacerbation

Exclusion Criteria

•Known allergy to magnesium sulfate
•History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease
•Use of oral steroid medication within 72 hours of presentation
•Radiographic evidence of pneumonia at presentation
•Administration of intravenous magnesium sulfate prior to study enrollment

Arms & Interventions

magnesium sulfate arm

magnesium sulfate with standard therapy

Intervention: Magnesium Sulfate

Outcomes

Primary Outcomes

Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma significantly reduce the time to clinical readiness for discharge?

Time Frame: 36 months

Secondary Outcomes

• Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease admission and readmission rate, compared to placebo(36 months)